<table cellpadding="0pt" cellspacing="0pt" id="_RefID0EPWBG" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics</caption>
<col width="16%"></col>
<col width="84%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Antiretrovirals</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.</paragraph>
<list listtype="unordered">
<item>Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance 
            
      
       <content stylecode="italics">[see Clinical Pharmacology (
             
       
        <linkhtml href="#Section_12.3">12.3</linkhtml>)].
            
      
       </content>
</item>
<item>Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity 
            
      
       <content stylecode="italics">[see Clinical Pharmacology (12.3)].</content>
</item>
<item>There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole.
           </item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>
<content stylecode="underline">Rilpivirine-containing products:</content> Concomitant use with omeprazole is contraindicated 
           
     
      <content stylecode="italics">[see Contraindications (
            
      
       <linkhtml href="#Section_4">4</linkhtml>)]
           
     
      </content>.
           
     
      <br/> 
           
     
      <br/>
<content stylecode="underline">Atazanavir:</content> Avoid concomitant use with omeprazole. See prescribing information for atazanavir for dosing information.
           
     
      <br/> 
           
     
      <br/>
<content stylecode="underline">Nelfinavir:</content> Avoid concomitant use with omeprazole. See prescribing information for nelfinavir.
           
     
      <br/> 
           
     
      <br/>
<content stylecode="underline">Saquinavir:</content> See the prescribing information for saquinavir for monitoring of potential saquinavir-related toxicities.
           
     
      <br/> 
           
     
      <br/>
<content stylecode="underline">Other antiretrovirals:</content> See prescribing information for specific antiretroviral drugs.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Warfarin</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Methotrexate</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted 
           
     
      <content stylecode="italics">[see Warnings and Precautions (
            
      
       <linkhtml href="#Section_5.18">5.11</linkhtml>)].
           
     
      </content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>A temporary withdrawal of omeprazole may be considered in some patients receiving high-dose methotrexate.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam)</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Clopidogrel</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition 
           
     
      <content stylecode="italics">[see Clinical Pharmacology (
            
      
       <linkhtml href="#Section_12.3">12.3</linkhtml>)].
           
     
      </content>
<br/>There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel
           
     
      <content stylecode="italics">.</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Avoid concomitant use with omeprazole. Consider use of alternative anti-platelet therapy 
           
     
      <content stylecode="italics">[see Warnings and Precautions (
            
      
       <linkhtml href="#Section_5.20">5.6</linkhtml>)].
           
     
      </content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Citalopram</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Increased exposure of citalopram leading to an increased risk of QT prolongation 
           
     
      <content stylecode="italics">[see Clinical Pharmacology (
            
      
       <linkhtml href="#Section_12.3">12.3</linkhtml>)]
           
     
      </content>.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Limit the dose of citalopram to a maximum of 20 mg per day. See prescribing information for citalopram.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Cilostazol</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Increased exposure of one of the active metabolites of cilostazol (3,4-dihydro-cilostazol) 
           
     
      <content stylecode="italics">[see Clinical Pharmacology (
            
      
       <linkhtml href="#Section_12.3">12.3</linkhtml>)].
           
     
      </content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Reduce the dose of cilostazol to 50 mg twice daily. See prescribing information for cilostazol.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Phenytoin</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Potential for increased exposure of phenytoin.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Monitor phenytoin serum concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for phenytoin.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Diazepam</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Increased exposure of diazepam 
           
     
      <content stylecode="italics">[see Clinical Pharmacology (
            
      
       <linkhtml href="#Section_12.3">12.3</linkhtml>)]
           
     
      </content>.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Monitor patients for increased sedation and reduce the dose of diazepam as needed.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Digoxin</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Potential for increased exposure of digoxin 
           
     
      <content stylecode="italics">[see Clinical Pharmacology (
            
      
       <linkhtml href="#Section_12.3">12.3</linkhtml>)].
           
     
      </content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Monitor digoxin concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See digoxin prescribing information.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole)</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Mycophenolate mofetil (MMF): Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving omeprazole and MMF. Use omeprazole with caution in transplant patients receiving MMF 
           
     
      <content stylecode="italics">[see Clinical Pharmacology (
            
      
       <linkhtml href="#Section_12.3">12.3</linkhtml>)]
           
     
      </content>.
           
     
      <br/> 
           
     
      <br/>See the prescribing information for other drugs dependent on gastric pH for absorption.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Combination Therapy with Clarithromycin and Amoxicillin</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated. Amoxicillin also has drug interactions.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>See 
           
     
      <content stylecode="italics">Contraindications, Warnings and Precautions  </content>in prescribing information for clarithromycin.
           
     
      <br/> 
           
     
      <br/>See 
           
     
      <content stylecode="italics">Drug Interactions </content>in prescribing information for amoxicillin.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Tacrolimus</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19
           
     
      <content stylecode="italics">.</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Monitor tacrolimus whole blood concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Interactions with Investigations of Neuroendocrine Tumors</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors 
           
     
      <content stylecode="italics">[see Warnings and Precautions (
            
      
       <linkhtml href="#Section_5.17">5.10</linkhtml>), Clinical Pharmacology (
            
      
       <linkhtml href="#Section_12.2">12.2</linkhtml>)]
           
     
      </content>.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Temporarily stop omeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Interaction with Secretin Stimulation Test</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Temporarily stop omeprazole treatment at least 14 days before assessing to allow gastrin levels to return to baseline 
           
     
      <content stylecode="italics">[see Clinical Pharmacology (
            
      
       <linkhtml href="#Section_12.2">12.2</linkhtml>)]
           
     
      </content>.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">False Positive Urine Tests for THC</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>An alternative confirmatory method should be considered to verify positive results.
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Other</content>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram).
           
     
      <br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="top">
<paragraph>Monitor patients to determine if it is necessary to adjust the dosage of these other drugs when taken concomitantly with omeprazole.
           
     
      <br/>
</paragraph>
</td>
</tr>
</tbody>
</table>